F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
What industry is F-star, an invoX company in?
F-star, an invoX company operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is F-star, an invoX company based?
F-star, an invoX company is headquartered in Cambridge, United Kingdom.
Find investors for your startup like F-star, an invoX company
Gritt sends AI-personalised outreach to each investor — from your Gmail
